- Home
- NAMS vs TVTX Comparison
NAMS vs TVTX Comparison
Compare NAMS & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | TVTX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | NAMS | TVTX |
|---|---|---|
| Price | $32.69 | $29.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | ★ $47.33 | $36.85 |
| AVG Volume (30 Days) | 666.3K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $38.17 | $44.75 |
| Revenue Next Year | $573.62 | $26.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.06 | $12.91 |
| 52 Week High | $42.00 | $42.13 |
Technical Indicators
Market Signals| Indicator | NAMS | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 46.02 |
| Support Level | $30.34 | $27.01 |
| Resistance Level | $37.43 | $31.44 |
| Average True Range (ATR) | 1.82 | 1.69 |
| MACD | -0.12 | 0.14 |
| Stochastic Oscillator | 5.46 | 57.81 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.